Method of 3,5-diammino-6-1,2,4-triazine derivatives making

U.S. Patent No. 3,637,688 discloses compounds of Formula II

<img file="CS234018B2_D0001.tif" />

in which

R₁ represents hydrogen or fluorine; and

R², R 6 and R 6 are hydrogen, fluoro or trifluoromethyl provided that at least one

3 The 4 substituent of R, R, R and R represents fluoro or trifluoromethyl, which compounds are useful in the treatment of malaria.

In the Rees article mentioned above, the 4-trifluoromethylphenyl compound of formula (II) wherein R is² = R¹ H is less toxic than the chlorophenyl compounds while still being effective against malaria. The other fluoro and trifluoromethyl compounds mentioned in this article are substantially less active than the 4-trifluoromethylphenyl compound.

Rosenburg and Bottiroli Why. Soc. exp. Blol., 1964, 115, 410 described a series of tests in which three antimalarial agents, quinacrine, chloroquine and hydroxychloroquine were tested as anticonvulsants. Only hydroxychloroquine had a favorable activity profile.

It has now been found that a group of novel compounds, 3,5-diamino-6- (phenyl) -1,2,4-triazines, is active in the treatment of diseases of the central nervous system, such as psychiatric neurological diseases, and these compounds are particularly preferred as anticonvulsants, for example in the treatment of epilepsy. Furthermore, it is believed that these triazines at the appropriate therapeutic doses do not have a depressive effect and are therefore advantageous compared to depressant antiepileptics such as phenobarbitone.

The present invention provides a process for the preparation of 3,5-diamino-6-phenyl-1,2,4-triazine derivatives of formula III

R¹¹ h₂n - &lt;/

N = N

<img file="CS234018B2_D0002.tif" />

(lil) in which

<td>R⁶R⁷R⁶ and R⁷R⁸R⁹R¹⁰R^{1 1}</td><td>represents chlorine, bromine, iodine, methyl or trifluoromethyl, represents hydrogen, chlorine or bromine or forms -CH = CH-CH = CH-, represents hydrogen or bromine, represents hydrogen, chlorine or bromine, represents hydrogen, methyl or fluorine and is amino, acetamido or</td>

dimethylaminomethylethyleneamino with the proviso that at most two of the substituents R? to Rⁱ⁰ are other than hydrogen and that the substituents R? to R¹⁰ not all hydrogen when R^b is chlorine, or an acid addition salt thereof, characterized in that the compound of formula (IV) is cyclized

<img file="CS234018B2_D0003.tif" />

vn Snž ^κ° to Η^1ΰ are as defined herein, whereupon the amino group of the substituent is optionally substituted ^r11 to convert the substituent ^r11 . no acetamido group^bo dimethyleminomethyleneamino.

A preferred embodiment is a process for producing a 3,5-diamino-6-phenyl-1,2,4-triazine of formula III, wherein: ^r6 represents chlorine, bromine, iodine, methyl or trifluoromethyl,

9

R 6 and R 6 are hydrogen, chlorine or bromine, ^r8 is hydrogen or bromo, r '0 is hydrogen or fluoro and r' 1 is amino,

10 with the proviso that at most one of the substituents R @ 1 ¹ to R is other than hydrogen, and that the R? to r'0 are not. all of the hydrogens when R @ 8 is C1-Cl, or an acid addition salt thereof. Preferably compound o is cyclized^becn^éhof formula I^IN, ^tode su^bstituent^{y r8}and ^r10 they have^withe uve^dmeaning. Cy^yThe ligation is preferably carried out in al^to% of an anol having from 1 to 4 carbon atoms, optionally in the presence of a strong base.

Preferred compounds of formula III are 3,5-diamino- ⁶- (2,3-di- or^F enyl) -1,2,4- tr^and az^andn

3,5-diamino-3,5-dihydro-oleol) 112,4-triazine

3,5-di amino-6- (4-bromo-2-chlorophenyl) -1,2,4-triazine

3,5-diamino-η 5 -Srom-2-halophenol) 112,4-triazine

3,3'-diE-4'-no --- (2,3,5-trichlorophenyl) -12,4-triazine

3,5-diamino --- (2-c) fluoro-6-fluorophenol-12,4-triazine,

3,5-di amino-6- (2-ethylphenyl) -12,4-triazine

3,5-diamino-6- (2-trifluoromethylleeol) -1,2,4-triazine

3,5-diamino-6- (2-bromophenyl) -1,2,4-triazine

3,5-diamino-6- (2-diphenyl) -12,4-triazine

3,5-diamino --- (2-Sromo-1-hloorpheol) 12,4-triazine

3,5-diamino-4-naphthyl-1,2,4-triazine. 5-Acetyl-4- (2,3-dimethoxyphenol) -1,2,4-triazine

3-Amino-6- (2,3-dichlorophenyl) -5-diethylthio-1,2,4-triazine

3,5-diamino-6- (1-naphthyl) 1,2,4-triazine

3.5- diaminno-6-3-_C(1-naphthyl) 1,2,4-triazine.

The present invention also 'discloses the first practical medical use of the compounds of formula III as previously defined. Preferably, they can be used to treat diseases of the central nervous system, especially epilepsy and humans. The present invention also provides pharmaceutical compositions comprising a compound of formula III in admixture with a pharmaceutically acceptable carrier. Suitable acid addition salts of the compound of formula (III) include those formed with organic and inorganic acids. Such acid addition salts are normally pharmaceutically acceptable. Preferred salts include salts with hydrochloric, sulfuric, citric, tartaric, phosphoric, lactic, pyrroleic, acetic, succinic, oxalic, coumaric, meaeinic, oxaloacetic, methanesulfonic, p-toluenesulfonic and benzenesulfonic acids. '

The compounds of formula III are present in the compositions of this invention in an effective unit dosage form, i.e., in a quantity sufficient to be effective against CNS diseases in vivo.

The pharmaceutically acceptable carriers present in the compositions of the present invention are the materials recommended^{é p}ro ^atfront^ypdrug delivery. These can be those of kappa or matuota tuff that are otherwise inert or medically suitable and are compatible with the active ingredients.

These pharmaceutical compositions may be administered orally or parenterally, may be used as a suppository or administered topically as an ointment, cream or powder. However, oral or oral administration of these compositions is preferred.

For oral administration, the fine powders or grandes contain diluents, disintegrating and / or surface-active agents and may be present in the form of a talc, water or syrup, in caps or shells, in a dry state in a non-aqueous suspension, the suspending agent being in suspension. or a suspension in water or syrup. Flavoring, preserving, suspending, thickening or emulsifying agents may be present, if desired or necessary.

When a suspension in water is prepared according to the invention, at least one such composition will be present.

For parenteral administration, these compounds may be present in sterile aqueous injection solutions which may contain altitoxides or buffering agents.

As mentioned above, the free base or a salt thereof can be administered in its pure form without other additives, in which case capsules or shells are the preferred carrier.

Alternatively, the active compound may be present in pure form, as an effective unit dose, for example, in a tablet or the like.

Other compounds which may be included are, for example, medically inert ingredients, for example solid or liquid diluents such as lactose, starch, or calcium phosphate for tablets or capsules, olive oil or ethyl oleate for soft capsules, and water or vegetable oil for suspensions or emulsions, oily. agents such as talc or mtagiesium stearate; means, such as carcasses, thickening agents, such as tragacanth resin or sodium alginate; and other therapeutically acceptable additives such as surfactants, preservatives and antitXing agents which are suitable as carriers in these compositions.

Tablets or other forms of administration formed in separate units may suitably contain a certain amount of a compound of Formula III that is effective at this dose or a multiple thereof, for example, in units of 5 to 500 milligrams, usually about 10 to 250 mg.

The pharmaceutical compositions of this invention are prepared by admixing a compound of formula III with a pharmaceutically acceptable carrier. Conventional pharmaceutical excipients may be admixed as desired.

The present invention provides a method of treating seizures in mammals, and in particular epilepsy in humans, by administering a nontoxic anticonvulsant agent of a compound of formula III or a salt or mixture as defined above.

As mentioned above, compounds of formula III are generally useful in the treatment of such diseases by oral administration or injection. (ip or p. c ·).

The compounds of formula III are normally administered orally at a dosage of from 0.1 mg / kg to 30 vд / kg per day. The dosage range for adult humans is usually from 8 mg to 2400 mg per. day and preferably 35 to 1050 mg per day. Due to the fact that these compounds of formula III. extremely long acting, it is often advantageous to administer them at an initial dose of 70 to 2400 mg on the first day and then at a lower dose of 20 to 1200 mg on the following days.

The cyclization reaction is normally carried out by heating in a 1-4 carbon atom danol solvent. Methianol and ethanol are particularly suitable solvents for this reaction. The reaction is preferably carried out in the presence of a strong base; potassium hydroxide is a particularly suitable base.

At ^eventravě s^lsu^Ceoioy. Father's formula^III_&gt; where ^r11 je ace^tami^da group of compounds of formula IU in which ^r11 is an amino group, lets. react with a suitable reactive acetic acid derivative, e.g. acid anhydride,. acid chloride, activated ester, or acid alone in the presence of the composition in a suitable solvent. This reaction is carried out by methods well known to those skilled in the art.

Particularly suitable derivatives are anhydride and hClgeoids. In these cases, the reaction is preferably carried out in acetic acid or pyridine.

For the preparation of a compound of formula (III) wherein r '' is a dimethylmethymethylene methylene group. with general formulas^ANDAND^ANDwhere ^r1'is aMnno ^ joina, necM zrea^Gwith a slight excess of a suitable activated camera derivative; which is a precursor for dimethylaminomethylamino, by methods well known in the art. those skilled in the art. The reaction was suitably carried out in the presence of a solvent and with an increase in the reaction^withen^E tepsty^, eg ^^ á between ⁵⁰ and^of 150 [deg.] C. Treatment of the product is normally carried out in an aqueous medium to ensure that the desired compound is formed such that the amino spot is substituted at the 5-position of the phenyl ring.

The compounds of formula (IV) are novel intermediate products.

The preparation of the compounds of formula (IV) is intended for synthesis. disclosed in the literature, i.e., U.S. Patent No. 3,637,688, for structurally related compounds.

The following examples prepare the compounds of this invention and their activities

CNS.

Example la d-1

Preparation of 3,5-Uicaino-6- (2,3-dichlorophenol-1,2,4-theory)

2, ChlSebeozOsnanoic acid

A solution of 2,3-uicKlse iodobenzene (37.3 g 0.14 N) in sodium-dried ether (300 m) was added dropwise to magnesium tricycles (3.65 g, 0.15 mol) and an iodine crystal while heating by forming a Grignard reagent.

The mixture was stirred and refluxed for 2 hours, then cooled and transferred dropwise under nitrogen to a stirred mixture of sodium dried ether (250 mL) containing solid carbon dioxide (about 100 g). The mixture was stirred for 2 hours, allowed to warm to room temperature overnight and then treated with ice (about 150 g) and 2N aqueous hydrochloric acid (75 mL) and the product was extracted with ether (200, 100 and 150 mL). The combined ether extracts were washed with water (2.40 mL) and then repeatedly extracted with 2N aqueous sodium hydroxide solution (100, 50 and 50 mL). The basic solutions were combined, stirred with activated carbon (3 g) for 10 minutes, filtered, and the cooled filtrate was acidified with concentrated hydrochloric acid (25 mL) at 10 ° C. The resulting solid was filtered off, washed with water (2.20 ml) and dried in vacuo.

Yield: 20.76 g (77.6% of theory), m.p. 167-169 ° C (not specified).

2.3- Dichlorobenzoyl chloride

A mixture of 2,3-dichlorobenzoic acid (39.4 g, 0.2 M) and thionyl chloride (100 mL) was refluxed for 2.5 hours. The cooled solution was evaporated in vacuo and distilled off under a nitrogen atmosphere. 35.5 g of compound (85%) were obtained, b.p.

2.3- Chlorobenzoyl cyanide

A mixture of potassium cyanide (36.9 g, 0.41 M) of potassium iodide (68.5 g, 0.41 M) and xylene (400ml) was heated under reflux in a nitrogen atmosphere under Bean and Stark separator for 24 hours so to remove all traces of water. and

A solution of 2,3-dichlorobenzoyl chloride (35.5 g, 0.17 M) in sodium-dried xylene (130 mL) was added dropwise to the above mixture of dry specific cyanide and xylene. The resulting mixture was stirred and refluxed for an additional 72 hours. The cooled mixture was filtered and the solid was washed well with xylene-dried sodium (200 mL). The filter and washings were combined and evaporated in vacuo to give an oil. 32 g of compound (94%) were obtained. / ·· ..

3 »5-No. amino-6- (2,3-dichlorophenyl) -1,2,4-triazine

A solution of 2,3 dichlorobenzoyl cyanide (32 g, 0.16 M) in dimethylsulfoxide (80 mL) was added dropwise to a stirred suspension of aminoguanidine bicarbonate (81.67 g, 0.6 M) which was treated with 6N aqueous nitric acid ( 400 ml) at about 25 ° C. The mixture was stirred for 3 hours and then allowed to stand at room temperature for 7 days. The cooled mixture was stirred and basified with 0.880 aqueous ammonia (400 mL) at 20 ° C and then stirred under ice-cooling for 30 minutes, filtered off and the resulting solid was washed thoroughly with water and finally dried in vacuo.

The above solid was added to a 10% solution of potassium hydroxide pellets in methanol (400 mL) and the solution was heated to reflux for 1.5 hours. When the solution was cooled, it was then evaporated in vacuo, treated with ice water (800 ml) and then stirred for 30 minutes and filtered. The solid residue was dried and recrystallized from isopropanol to give 3,5-diamino-6- (2,3-dichlorophenyl) -1,2,4-triazine. Yield 6.8 g (15.6%), m.p. 216-218 ° C (not specified).

In a manner analogous to that described in Example 1, compounds of formula (V) whose composition, properties and yields are shown in Table 1 and compounds of formula (VI) whose composition, properties and yields are shown in Table 2 were prepared.

Example 2 where

R⁶ = CF₃, CH₃, Cl, Br and I,

R⁸ = H, Br,

В⁹ = H, Cl, Br, r &amp; apos; = H, F.

<img file="CS234018B2_D0004.tif" />

(V) (VI) where

R⁹ = H, Cl, R¹⁰ = H, CH₃.

Table 1

<td>Vi R</td><td>Thawing temperature (unspecified)</td><td>% yield (from acid)</td>

<td>2,5-Cl₂</td><td>22 ° to 230 ° C</td><td> 2</td>

<td>2-Cl, 4-Br</td><td>Mp 223-225 ° C</td><td> 6</td>

<td>2-Cl, 5-Br</td><td>238 DEG-240 DEG</td><td> 2</td>

<td> 2-^CF3</td><td>Mp 177-178 ° C</td><td> 0,4</td>

<td>2-Cl, 6-F</td><td>Mp 226-228 ° C</td><td> 14,5</td>

<td>2-CH₃</td><td>Mp 181-183 ° C</td><td> 25</td>

<td>2-Br</td><td>Mp 204-207 ° C</td><td> 34</td>

2340.18

Table 1 continued

<td>IN; R</td><td>Melting point (not specified)</td><td>% yield (from acid)</td>

<td> 2-1</td><td>Mp 219-222 ° C</td><td> 7</td>

<td>2-Br, 5-Cl</td><td> 255 ^andmp 256 ° C</td><td> ' »2</td>

Table 2

<td>VI; R</td><td>Melting point (not specified)</td><td>% yield (from acid)</td>

<td>H</td><td>Mp 215-216 ° C</td><td> 7,5</td>

<td>2-CH3</td><td>Mp 131-134 ° C</td><td> 0.3</td>

<td>3-C1</td><td>285-286 ° C</td><td> ',0</td>

Example 3

Preparation of 3,5-diamino-6- (2,3,5-trichlorophenyl-1,2,4-triazine) 2,3,5-Trichlorobenzoic acid

Sodium nitrite powder (37.0 g, 0.54 M) was. added portionwise to concentrated sulfuric acid (270 d), which was stirred under a nitrogen atmosphere. The temperature was maintained^pfrom value ⁷⁰ ° C · Meanwhile, it was a fuss^t3-aminof2,5-^eichloгb ¢ ozffv^and to^yseline (100 g, 0.45 M) in hot glacial acetic acid (1200 dl), the resulting solution was quickly cooled to room temperature and added dropwise to the above and cooled mixture.^1П^ о¹ nitrous ^tand^to, ab^y the inlet temperature did not exceed 30 ° C.

The solution formed after the addition was left at room temperature for 2 hours, then was added slowly to a stirred solution of cuprous chloride (97 g, 0.97 M) in concentrated hydrochloric acid (970 mL). The mixture was stirred until the nitrogen evolution ceased and was left overnight. It was a solid, washed well with water and water^yvacuum dried. ^Bylo zi ^ sk ^ o ^{90.1 g} of compounds^{1 (8}9 %, ^ fence ^táoand ¹⁶⁴ and^of 165 °^C(not specified).

2.3.5- TrichLorbenzo^y1chLorid

Mixture of 2,3,5-OgiclObbonzo k^yselioy (90 g, 0.4 M) and dimethylformamide (1 µm) in thifoyl chloride (200 m) were heated under reflux for 2.5 hours. The oily solution was evaporated in vacuo and the residue distilled off under a nitrogen atmosphere; It was from^andsk^andno ^89,2 g (⁹⁰ $) compounds boiling point ¹⁵⁸ and^{ž 160} ° C at ambient temperature ⁴ 000 ^pand.

2.3.5- Trichlfrbenzoylk1aoie

A mixture of cuprous cyanide (89 g, 0.9 M) of potassium iodide (150.5 g, 0.9 M) and xylene (800 m) was heated to reflux in a nitrogen atmosphere under Dean a. .

A solution of 2,3,5-trichlorobenzoyl chloride (89 g, 0.46 M) in sodium-dried xylene (100 mL) was added to the above mixture. The resulting mixture was stirred and refluxed for an additional 72 hours. The cooled mixture was filtered and the solid was washed thoroughly with sodium-dried xylene (200m). The filtrate and wash liquors were combined and evaporated in vacuo to give 1 H 2. Yield: 76 g (96.5).

3,5-Diamino-4- (2,3,5-trifluorophenyl) -1,2,4-thiazine x

A solution of 2,3,5-ore-bis-benzoyl-cyanide (38.5 g, 0.16 M) in dimethhlsHf oxide (80 m) was added dropwise to a stirred suspension of aminogeine pyridine bicarbonate (65.76 g) 0 ', 32 M) which was treated with 8 L aqueous nitric acid solution (560 m). The mixture was stirred for 35 hours and then allowed to stand at room temperature for 21 hours. The solid was filtered, washed with water (2 · 100 · m) and dried in vacuo. The suspension of the dried material in a 10% solution of potassium hydroxide pellets in methanol (320 mL) was heated to reflux for 1 hour. The mixture was cooled and evaporated in vacuo. The residue was treated with ice water (200 mL) and the resulting solid was filtered and dried under vacuum.

This dried dry substance was transferred to the top of a dry column (25 mm diameter, 200 g of MFC silica gel) and eluted with ethyl acetate (methanol) acetic acid (90: 2, 5: 2.5). Fractions 50 to 80 (900 drops per fraction) were combined and evaporated in vacuo. The resulting solid was recrystallized from isopropanol to give 3,5-dihydro-6- (2,3,5-triiol).^Fen^Ol) -¹,2_{) l ·}⁴·^triazio. ·^INýtěže^to 0,77 ^{g (1}, 6%) of melting point ²³² to 2³⁵ ° C (not specified).

Example 4,

Preparation of 5-acetamido-2-a-onool - (-, 3-diciloool) 12,4-thiazine

Solution 3, 5-dialinol66 (2, 3, 10-olol) 12_&gt;4-thiazia (2 g, 8 mM) and acetic anhydride (10 mL) in acetic acid (20 mL) were stirred and refluxed for 2 hours. The solution was then cooled and evaporated in vacuo. The residue was treated with aqueous 0.880 ammonia (100 mL) and the resulting mixture was stirred for 2 hours. The solid was collected by filtration, dried, then recrystallized from propane to give 5-diethylamino-3- min-6- (2,3-diclorophen).ⁿl)) 1,1'-azine. ^INýtě^ofE^{k 1},^{0 G} · ⁽ 42%, melting point ²⁵⁰ and^of 252 ° C (not specified).

Above 5

Preparation of 3-Amino-6- (2,3-dichlorophenyl) -5,5-dimethylaminoethyl ethyl 1,2,4-thiazinol oxalate (1 mL) was added dropwise to a stirred network of 3,5-diaminool ((.beta.-dimethylol)) 112,4-triazine. (1 g, 4 mM) in dry dimethylHomamide (20 mL) in a nitrogen atmosphere. Mixture^byla mingled and filmed on ¹²⁰ Deň: 32 ° C ^po dHu 2 ^hodio^, the solution was cooled and evaporated in vacuo. The resulting H 2 was washed once with water (20m), then dissolved in a solution of oxalic acid (1g) in methanol (20m). Ether (100 m.) Precipitated Hey, who slowly crystallized).

The crude material was recrystallized from aqueous isopropanol to give 3-amino-6- (2'-dichlorophenyl) -5,5-dimethylthio-10-ethyl-ethylolino-1,2,4-thiazolyl oxalate. Yield 0.19 g⁽¹4 %, melting point P 2 a^of П5 °^C (no solution).

Example 6

The pharmacological activity of some of the compounds of the invention represented by the general formula (VII) was investigated

<img file="CS234018B2_D0005.tif" />

(VII) where

R⁶ = CH₃, CF₃, Cl, Br, I,

R⁷ = H, Cl,

R⁸ = H, Br,

R⁹ = H, Cl, Br,

R¹⁰ = H, F,

R¹¹ = NH₂NHCOCH3 N = CHN (CH₃)₂.

Anticonvulsant efficacy was determined by the standard maximum electroshock test as described by LA Woodbury and VD Davenport, Arch. Int. Pharmacodyn. 1952, 92, 97.

Table 3

<td>VII; R</td><td>VII; R¹¹</td><td>ed₅₀, mes mice, mg / kg, po</td>

<td>2,3-Cl₂</td><td>NHg</td><td> 2,4</td>

<td>2,5-Cl₅</td><td>nh₂</td><td> 3,3</td>

<td>²“^GH3</td><td>NHg</td><td> 15,0</td>

<td>2-Cl, 4-Br</td><td>NHg</td><td> 12,8</td>

<td>2-Cl, 5-Br</td><td>NHg</td><td> 6,0</td>

<td>2-CF₃</td><td>NH₂</td><td> 20,0</td>

<td>2-Cl, 6-F</td><td>NHg</td><td> 12,2</td>

<td>2,3,5-Cl₃</td><td>NHg</td><td> 0,65</td>

<td>2-Br</td><td>NHg</td><td> 6,5</td>

<td> 2-1</td><td>NHg</td><td> 1 1 ,8</td>

<td>2-Br, 5-Cl</td><td>NHg</td><td> 4,6</td>

<td>2,3-Cl₂</td><td>NHCOCH₃</td><td> 5</td>

<td>2,3-Cl₂</td><td>n = chn (ch₃)₂</td><td> 5</td>

Table 4 shows the results of a standard electroshock assay for some compounds of Formula VI.

1

Table 4

VI; R

ED₅₀, MES mice, m / kg, po

H

2-CH

3-C1

2,9

16.5

6.5

LD-q (expressed in mg, per kg, p-o) of 3,5-diamine- (2,3-dichloro-phenyl) - -1,4,4-triazine and 3,5-diamino-6 - (2,5-dichlorophenyl) -1,2,4-triazine was determined in mice and rats. The LD 50 described is the dose at which 50% of the animals survive 10 days after administration of the compound. The results are shown in Table 5. ' '

Table 5

<td>Vil; R</td><td>• r ”</td><td>Mice</td><td>Sys</td>

<td>2,3-CL₂</td><td>NHg</td><td> 250</td><td> . 640</td>

<td>2,5-ΰ1₂</td><td>nh₂</td><td> 708</td><td> 640</td>

<td>Prescription composition</td><td>and a method of making tablets</td><td></td><td></td>

<td>Substance</td><td></td><td>Content in tablet</td><td></td>

<td>3,5-diamino-6- (2,3-dichloro-D-1,4-triazine)</td><td> 150</td><td>mg</td>

<td>lactose</td><td> 200</td><td>mg</td>

<td>cornstarch .</td><td> 50</td><td>mg</td>

<td>pollviyllplrrslidsy.</td><td> 4</td><td>mg</td>

<td>maggnsium stearate</td><td> 4</td><td>mg</td>

The drug was mixed with lactose and starch and granulated with a solution of polyvinilpyrrolidone in water. The resulting granules were dried, mixed with mεaglye stearate, and compressed to give tablets with an average hsSnst of 408 mg.